Veraxa Biotech (VRXA) Stock Statistics & Valuation Metrics
Total Valuation
Veraxa Biotech has a market cap or net worth of $168.42M. The enterprise value is $303.88T.
- Market Cap
- $168.42M
- Enterprise Value
- $303.88T
Share Statistics
Veraxa Biotech has 141,407,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 141,407,800
- Owned by Insiders
- 4.56%
- Owned by Institutions
- 0.19%
Financial Efficiency
Veraxa Biotech’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is -0.66%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- -0.66%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 0
- Profits Per Employee
- 1.12M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Veraxa Biotech is 50.75. Veraxa Biotech’s PEG ratio is -4571315157469574.00.
- PE Ratio
- 50.75
- PS Ratio
- 0.00
- PB Ratio
- -23.66
- Price to FCF
- -1311.48
- Price to Operating Cash Flow
- -828.42
- PEG Ratio
- -4571315157469574.00
Income Statement
In the last 12 months, Veraxa Biotech had revenue of 0 and earned 8.99M in profits. Earnings per share was 0.36.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -1.79M
- Pretax Income
- 8.99M
- Net Income
- 8.99M
- EBITDA
- -1.79M
- Earnings Per Share (EPS)
- 0.36
Cash Flow
In the last 12 months, operating cash flow was -412.70K and capital expenditures 0, giving a free cash flow of -412.70K billion.
- Operating Cash Flow
- -412.70K
- Free Cash Flow
- -412.70K
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Veraxa Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.14%
- Earnings Yield
- 3.51%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- -89.14%
- 50-Day Moving Average
- 1.34
- 200-Day Moving Average
- 6.93
- Relative Strength Index (RSI)
- 47.77
- Average Volume (3m)
- 255.66K
Financial Position
Veraxa Biotech as a current ratio of 0.15, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.15
- Quick Ratio
- 0.15
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.10
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Veraxa Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Veraxa Biotech EV to EBITDA ratio is -91.88, with an EV/FCF ratio of -736.33.
- EV to Sales
- 0.00
- EV to EBITDA
- -91.88
- EV to Free Cash Flow
- -736.33
- EV to Operating Cash Flow
- -736.33
Balance Sheet
Veraxa Biotech has $32.79K in cash and marketable securities with $0.00 in debt, giving a net cash position of $32.79K billion.
- Cash & Marketable Securities
- $32.79K
- Total Debt
- $0.00
- Net Cash
- $32.79K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$0.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Veraxa Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 2.24%
Scores
- Smart Score
- 6
- AI Score
- ―